| View |
|
DRP-14255-03
|
Metformin Hydrochloride
|
Thormin
|
850 mg
|
Film-Coated Tablet
|
Blood Glucose-Lowering Drug (Biguanide)
|
Azarias Pharmaceutical Laboratories Inc
|
Philippines
|
CLIDP Conversion
|
10 May 2024
|
04 August 2025
|
| View |
|
DRP-14322-01
|
Tacrolimus
|
Acrolim 0.03
|
300 mcg/g (0.03% w/w)
|
Topical Ointment
|
Agents for Dermatitis
|
The Madras Pharmaceuticals
|
India
|
CLIDP Conversion
|
10 May 2024
|
17 August 2028
|
| View |
|
DRP-14374-03
|
Cilostazol
|
Clostelo 50
|
50 mg
|
Tablet
|
Antithrombotic Agent (Platelet aggregation inhibitor)
|
Cooper Pharma Limited
|
India
|
CLIDP Conversion
|
10 May 2024
|
30 August 2028
|
| View |
|
DRP-14375-05
|
Dutasteride + Tamsulosin Hydrochloride
|
Urofix
|
500 mcg / 400 mcg
|
Capsule
|
Benign Prostatic Hypertrophy Drug (Alpha-Adrenoreceptor Antagonist)
|
Pell Tech Health Care Private Ltd.
|
India
|
CLIDP Conversion
|
10 May 2024
|
31 August 2028
|
| View |
|
DRP-14728-01
|
Pregabalin + Mecobalamin
|
Balmax
|
75 mg/ 750 mcg
|
Capsule
|
Antiepileptic- Vitamin (Cyanocobalamin Analogue) Combination
|
Unison Pharmaceuticals Pvt. Ltd. (Unit I)
|
India
|
CLIDP Conversion
|
10 May 2024
|
15 December 2028
|
| View |
|
DRP-14758-01
|
Sodium Hyaluronate
|
IKHSOD
|
1 mg / mL (0.1 % w/v)
|
Ophthalmic Solution (Eye Drops)
|
Dysfunctional Tear Syndrome (Lubricant)
|
Makcur Laboratories Limited
|
India
|
CLIDP Conversion
|
10 May 2024
|
12 December 2028
|
| View |
|
DRP-14777-02
|
Norepinephrine (as bitartrate)
|
Aenor
|
1 mg / ml (4 mg / 4 ml)
|
Solution for Injection (I.V. Infusion)
|
Adrenergic/ Dopaminergic Agent
|
Ultra Laboratories Private Limited
|
India
|
CLIDP Conversion
|
10 May 2024
|
03 January 2029
|
| View |
|
DRP-15020-01
|
Pemetrexed (as disodium)
|
Permetrizz
|
500 mg
|
Lyophilized Powder for Injection
|
Antineoplastic
|
Shanghai Chemo Wanbang Biopharma Co. Ltd.
|
China
|
CLIDP Conversion
|
06 May 2024
|
23 January 2029
|
| View |
|
DRP-15030-01
|
Co-Amoxiclav
|
Viamox
|
625 mg
|
Film-Coated Tablet
|
Antibacterial (Penicillin/Beta-Lactamase Inhibitor)
|
Baroque Pharmaceuticals Pvt. Ltd.
|
India
|
CLIDP Conversion
|
06 May 2024
|
21 March 2029
|
| View |
|
DRP-3522-10
|
Cetirizine Hydrochloride
|
Allerheal
|
5 mg/5 mL
|
Syrup
|
H1-Receptor Antagonist (Antihistamine)
|
Azarias Pharmaceutical Laboratories Inc.
|
Philippines
|
CLIDP Conversion
|
06 May 2024
|
01 February 2027
|
| View |
|
DRP-4204-05
|
Tranexamic Acid
|
Zetranex
|
500 mg
|
Capsule
|
Anti-Fibrinolytic
|
Azarias Pharmaceutical Laboratories Inc
|
Philippines
|
CLIDP Conversion
|
06 May 2024
|
08 February 2028
|
| View |
|
DRP-4457-02
|
Ascorbic acid (as Sodium ascorbate)
|
Corbamax
|
500 mg (equivalent to 562.43 mg Sodium ascorbate)
|
Capsule
|
Vitamin
|
Azarias Pharmaceutical Laboratories Inc
|
Philippines
|
CLIDP Conversion
|
06 May 2024
|
06 June 2028
|
| View |
|
DRP-4830-04
|
Fenofibrate
|
Fenomel
|
300 mg
|
Capsule
|
Lipid Modifying Agent (Fibrate)
|
Azarias Pharmaceutical Laboratories Inc
|
Philippines
|
CLIDP Conversion
|
06 May 2024
|
16 October 2028
|
| View |
|
DRP-4838-09
|
Fenofibrate
|
Fenomel
|
200 mg
|
Capsule
|
Lipid Modifying Agent (Fibrates)
|
Azarias Pharmaceutical Laboratories Inc
|
Philippines
|
CLIDP Conversion
|
06 May 2024
|
16 October 2028
|
| View |
|
DRP-4839-10
|
Fenofibrate
|
Fenolizen
|
160 mg
|
Capsule
|
Lipid Modifying Agent (Fibrates)
|
Azarias Pharmaceutical Laboratories Inc
|
Philippines
|
CLIDP Conversion
|
06 May 2024
|
16 October 2028
|
| View |
|
DRP-4985-07
|
Oxytocin
|
Rifoxyn
|
10 IU/mL
|
Solution for Injection (I.M./I.V./S.C.)
|
Posterior Pituitary Hormone
|
Umedica Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
10 May 2024
|
11 December 2028
|
| View |
|
DRP-5044-06
|
Fenofibrate
|
Fenomel
|
100 mg
|
Capsule
|
Hypertriglyceridemia
|
Azarias Pharmaceutical Laboratories Inc.
|
Philippines
|
CLIDP Conversion
|
06 May 2024
|
07 January 2029
|
| View |
|
DRP-5206-06
|
Ambroxol Hydrochloride
|
Mucobroze
|
30 mg
|
Tablet
|
Mucolytic
|
Azarias Pharmaceutical Laboratories Inc.
|
Philippines
|
CLIDP Conversion
|
06 May 2024
|
03 March 2029
|
| View |
|
DRP-5513-04
|
Bortezomib
|
BORTEGET
|
3.5 mg
|
Lyophilized Powder for Injection (IV)
|
Antineoplastic
|
Getwell Pharmaceuticals
|
India
|
CLIDP Conversion
|
07 May 2024
|
15 September 2029
|
| View |
|
DRP-5966-14
|
Co-Amoxiclav
|
Janclav 457
|
457 mg/5 mL
|
Powder for Suspension
|
Antibacterial
|
Giyaan Pharma Private Limited
|
India
|
CLIDP Conversion
|
03 May 2024
|
27 January 2030
|